Cantor Fitzgerald Weighs in on VERA FY2025 Earnings

Vera Therapeutics, Inc. (NASDAQ:VERA) – Stock analysts at Cantor Fitzgerald issued their FY2025 earnings estimates for Vera Therapeutics in a research report issued to clients and investors on Tuesday, January 21st. Cantor Fitzgerald analyst P. Stavropoulos forecasts that the company will post earnings of ($2.22) per share for the year. Cantor Fitzgerald has a “Overweight” rating and a $107.00 price objective on the stock. The consensus estimate for Vera Therapeutics’ current full-year earnings is ($2.89) per share.

Several other research firms also recently commented on VERA. Guggenheim lifted their price objective on Vera Therapeutics from $56.00 to $64.00 and gave the stock a “buy” rating in a report on Monday, October 28th. Wedbush lifted their price target on shares of Vera Therapeutics from $30.00 to $38.00 and gave the stock a “neutral” rating in a research note on Friday, November 8th. Scotiabank started coverage on shares of Vera Therapeutics in a research report on Wednesday, October 16th. They set a “sector outperform” rating and a $60.00 price objective on the stock. Wells Fargo & Company assumed coverage on shares of Vera Therapeutics in a report on Thursday, November 21st. They issued an “overweight” rating and a $70.00 target price on the stock. Finally, JPMorgan Chase & Co. boosted their target price on shares of Vera Therapeutics from $72.00 to $75.00 and gave the company an “overweight” rating in a research note on Tuesday, November 5th. One research analyst has rated the stock with a hold rating, six have given a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat, Vera Therapeutics has a consensus rating of “Buy” and an average price target of $63.50.

Vera Therapeutics Stock Up 0.9 %

Vera Therapeutics stock opened at $34.09 on Thursday. The firm has a market cap of $2.16 billion, a price-to-earnings ratio of -13.06 and a beta of 1.15. The company has a current ratio of 13.76, a quick ratio of 13.76 and a debt-to-equity ratio of 0.17. Vera Therapeutics has a 12 month low of $16.84 and a 12 month high of $51.61. The stock has a fifty day simple moving average of $42.82 and a two-hundred day simple moving average of $40.88.

Vera Therapeutics (NASDAQ:VERA) last announced its quarterly earnings data on Thursday, November 7th. The company reported ($0.85) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.64) by ($0.21).

Institutional Trading of Vera Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of VERA. Holocene Advisors LP boosted its holdings in Vera Therapeutics by 8.8% in the 3rd quarter. Holocene Advisors LP now owns 1,954,528 shares of the company’s stock worth $86,390,000 after buying an additional 158,451 shares during the period. Lord Abbett & CO. LLC boosted its stake in shares of Vera Therapeutics by 41.1% in the third quarter. Lord Abbett & CO. LLC now owns 426,014 shares of the company’s stock worth $18,830,000 after acquiring an additional 124,197 shares during the period. First Turn Management LLC boosted its stake in shares of Vera Therapeutics by 53.3% in the third quarter. First Turn Management LLC now owns 326,494 shares of the company’s stock worth $14,431,000 after acquiring an additional 113,550 shares during the period. Squarepoint Ops LLC raised its stake in Vera Therapeutics by 316.5% during the 2nd quarter. Squarepoint Ops LLC now owns 148,011 shares of the company’s stock valued at $5,355,000 after purchasing an additional 112,475 shares during the period. Finally, Pier Capital LLC purchased a new position in Vera Therapeutics in the 3rd quarter worth approximately $4,573,000. 99.21% of the stock is currently owned by institutional investors.

Insider Transactions at Vera Therapeutics

In other news, Director Beth C. Seidenberg sold 15,000 shares of the firm’s stock in a transaction dated Monday, October 28th. The stock was sold at an average price of $48.03, for a total value of $720,450.00. Following the transaction, the director now owns 131,553 shares of the company’s stock, valued at $6,318,490.59. This trade represents a 10.24 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Marshall Fordyce sold 17,500 shares of the business’s stock in a transaction that occurred on Wednesday, December 18th. The shares were sold at an average price of $43.07, for a total value of $753,725.00. Following the transaction, the chief executive officer now owns 85,942 shares of the company’s stock, valued at approximately $3,701,521.94. This trade represents a 16.92 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 67,500 shares of company stock worth $3,026,075 in the last 90 days. 21.70% of the stock is currently owned by insiders.

About Vera Therapeutics

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.